Pierre Fabre Refiles Ebvallo BLA After FDA Reversal

FDA has rejected tabelecleucel twice — and the second time, it rejected not the drug's safety or manufacturing but its own earlier judgment of the pivotal trial's adequacy. Pierre Fabre resubmitted the Biologics License Application for the Epstein-Barr virus-specific T-cell therapy, branded Ebvallo, on 30 September 2026, nine months after that reversal and five months after FDA agreed on a path back.

A reversal, not a routine rejection

Complete Response Letters are common; a CRL that reverses the agency's own prior read of a trial's adequacy is not. FDA's first rejection of tabelecleucel, in January 2025, was a manufacturing problem: inspection findings at a third-party facility, with no stated concern about the clinical data. Pierre Fabre and Atara resolved those findings. When FDA responded again in January 2026, the manufacturing issue was gone — but FDA now said the single-arm ALLELE trial it had previously treated as adequate to support accelerated approval was, on a second look, potentially confounded by its design, conduct or analysis. For a company that believed it had cleared the substantive bar on its first attempt, that is a materially different kind of no.

What the Type A meeting settled

Sponsors facing a CRL that reopens an evidentiary question request a Type A meeting to find out, in plain terms, what would change FDA's mind. Pierre Fabre's meeting completed around 7 May 2026. FDA's agreement, as the company has characterized it: a single-arm trial with an appropriate historical control, conducted in a pre-specified manner, remains capable of serving as adequate and well-controlled evidence for accelerated approval — the same general standard FDA had applied the first time, now tied explicitly to prespecification and control selection. The resubmission filed 30 September answers that standard with expanded ALLELE follow-up (75 patients with rituximab-refractory PTLD: a 50.7% objective response rate, 28.0% complete response rate, 23.0-month median duration of response, and 18.4-month median overall survival), plus data from the drug's expanded-access program and its existing commercial use in Europe, where it is already marketed as Ebvallo.

Who is filing, and why it matters

Atara Biotherapeutics discovered and originally developed tabelecleucel. In July 2025 it transferred clinical and development responsibility to Pierre Fabre; in October 2025 it went further, transferring all regulatory activities — including sponsorship of the BLA itself — to Pierre Fabre, which now bears the cost of U.S. regulatory work and is obligated to use commercially reasonable efforts toward approval. Atara keeps an economic stake: a milestone payment is due to it on approval, and the company continues to appear as the filer on SEC disclosures because it remains publicly traded, even though Pierre Fabre is now the party FDA deals with directly.

The read for other sponsors

An accelerated-approval pathway built on a single-arm trial always carries evidentiary risk that is partly a matter of FDA's judgment, not just the data. This case shows that judgment can shift between submissions even when nothing about the trial itself has changed — and that the fix, when it comes, can be procedural (prespecification, control selection) rather than a demand for a new trial. For sponsors planning accelerated-approval programs on single-arm evidence, the operational lesson is to treat FDA's read of "adequate and well-controlled" as a standard to document and defend at every review cycle, not a box checked once.

Frequently asked questions

What is tabelecleucel and what is it for?

Tabelecleucel (Ebvallo) is an allogeneic EBV-specific T-cell immunotherapy. The resubmitted BLA seeks approval for adults and children 2 and older with relapsed or refractory EBV-positive post-transplant lymphoproliferative disease who have received at least one prior therapy, following solid organ or hematopoietic cell transplant.

Why did FDA reject the application twice?

A first CRL on 15 January 2025 cited third-party manufacturing/GMP inspection findings, not the clinical data. A second CRL in January 2026, after those issues were resolved, reversed FDA's earlier position that the single-arm ALLELE trial was adequate for accelerated approval, citing potential confounding in the trial's design, conduct and analysis.

What changed to allow a third submission?

A Type A meeting completed around 7 May 2026 in which FDA agreed a single-arm study with an appropriate historical control, run in a pre-specified manner, could still serve as adequate, well-controlled evidence. The 30 September 2026 resubmission adds expanded ALLELE follow-up plus expanded-access and European commercial-experience data.

Who holds the BLA now?

Pierre Fabre Pharmaceuticals now sponsors the BLA, after Atara Biotherapeutics transferred development responsibility in July 2025 and all regulatory activities, including BLA sponsorship, in October 2025. Atara remains economically interested via an approval milestone payment.